Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections

Vicuron Pharmaceuticals88 enrolled

Overview

This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters (CR-BSI). The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Bacteremia

Interventions

dalbavancinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

* The patient or his/her legally authorized representative has given informed consent by means approved by the investigator's IRB/EC; * \> 18 years of age; * Had one or more central venous catheters at the time initial signs of infection were evident; * Creatinine clearance \<50 mL/min; * Bilirubin \> 2x the upper limit of normal; * Treatment with an antibiotic effective against Gram-positive bacterial infections for more than 24 hours within 48 hours of study medication initiation, * Prolonged antibiotic therapy for CR-BSI anticipated (i.e., \>2 weeks)

Locations (1)

Wellstar/Kennestone Hospital

Marietta, Georgia, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.